Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

[1]  Iris Antes,et al.  Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease , 2012, Antimicrobial Agents and Chemotherapy.

[2]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[3]  J. Bukh,et al.  Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. , 2011, Gastroenterology.

[4]  D. Neau,et al.  Hepatitis C virus (HCV) protease variability and anti‐HCV protease inhibitor resistance in HIV/HCV‐coinfected patients , 2011, HIV medicine.

[5]  S. Locarnini,et al.  Hepatitis C virus resistance to protease inhibitors. , 2011, Journal of hepatology.

[6]  Jean-Michel Pawlotsky,et al.  Treatment failure and resistance with direct‐acting antiviral drugs against hepatitis C virus , 2011, Hepatology.

[7]  C. Schiffer,et al.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding , 2010, Proceedings of the National Academy of Sciences.

[8]  I. Vandenbroucke,et al.  Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing , 2010, Journal of Virology.

[9]  L. Vrang,et al.  In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435 , 2010, Antimicrobial Agents and Chemotherapy.

[10]  F. S. Domingues,et al.  Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients , 2009, Hepatology.

[11]  J. McHutchison,et al.  Antiviral resistance and specifically targeted therapy for HCV (STAT‐C) , 2009, Journal of viral hepatitis.

[12]  J. Nachega,et al.  Combined antiretroviral treatment initiation during hospitalization: outcomes in South African adults. , 2009, Journal of acquired immune deficiency syndromes.

[13]  A. Lazzarin,et al.  Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. , 2009, Journal of acquired immune deficiency syndromes.

[14]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[15]  E. Emini,et al.  Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034) , 2008, Antimicrobial Agents and Chemotherapy.

[16]  J. Courcambeck,et al.  Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. , 2008, AIDS.

[17]  A. Moya,et al.  Mapping Natural Polymorphisms of Hepatitis C virus NS3/4A Protease and Antiviral Resistance to Inhibitors in Worldwide Isolates , 2008, Antiviral therapy.

[18]  H. Chu,et al.  Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease , 2007, Antimicrobial Agents and Chemotherapy.

[19]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[20]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[21]  B. Clotet,et al.  Genetic and catalytic efficiency structure of an HCV protease quasispecies , 2007, Hepatology.

[22]  V. Pazienza,et al.  In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. , 2006, The Journal of antimicrobial chemotherapy.

[23]  X. Tong,et al.  Computational Study of the Effects of Mutations A156T, D168V, and D168Q on the Binding of HCV Protease Inhibitors. , 2006, Journal of chemical theory and computation.

[24]  M. Winters,et al.  Hepatitis C Virus Protease Gene Diversity in Patients Coinfected with Human Immunodeficiency Virus , 2006, Journal of Virology.

[25]  S. Lemon,et al.  Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor , 2006, Journal of Biological Chemistry.

[26]  B. Picard,et al.  Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients , 2005, Journal of Medical Virology.

[27]  D. Lamarre,et al.  Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061 , 2004, Journal of Virology.

[28]  John R Fulghum,et al.  In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 , 2004, Journal of Biological Chemistry.

[29]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[30]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[31]  M. Rapicetta,et al.  Molecular characterisation of HCV genotype 4 isolates circulating in Italy , 2000, Journal of medical virology.